Evidence map›Paper›PMID 34036229›Full record

ArticleJCO precision oncology2021

Excellent Response With Alpelisib and Bicalutamide for Advanced Salivary Duct Carcinoma With PIK3CA Mutation and High Androgen Receptor Expression-A Case Report.

Hardik Sheth, Prashant Kumar, Aditya Shreenivas, Janani Sambath, Ramya Pragya, Chetan Madre, Nevitha Athikari, Hemant Khandare, Vishal Peshattiwar, Rajan Datar and 1 more

Open access · hybridAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in JCO precision oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
2.9field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 16 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 2 countries.

Hardik ShethKokilaben Dhirubhai Ambani Hospital and Medical Research Institute, Mumbai, India.
Prashant KumarInstitute of Bioinformatics, Bangalore, India.
Aditya ShreenivasDepartment of Medical Oncology, Medical College of Wisconsin, Milwaukee, WI.
Janani SambathInstitute of Bioinformatics, Bangalore, India.
Ramya PragyaKokilaben Dhirubhai Ambani Hospital and Medical Research Institute, Mumbai, India.
Chetan MadreKokilaben Dhirubhai Ambani Hospital and Medical Research Institute, Mumbai, India.
Nevitha AthikariKokilaben Dhirubhai Ambani Hospital and Medical Research Institute, Mumbai, India.
Hemant KhandareKokilaben Dhirubhai Ambani Hospital and Medical Research Institute, Mumbai, India.
Vishal PeshattiwarKokilaben Dhirubhai Ambani Hospital and Medical Research Institute, Mumbai, India.
Rajan DatarDepartment of Research and Innovations, Datar Cancer Genetics Limited, Nasik, India.
Sewanti LimayeKokilaben Dhirubhai Ambani Hospital and Medical Research Institute, Mumbai, India.
Kokilaben Dhirubhai Ambani Hospital · INManipal Academy of Higher Education · INDatar Cancer Genetics (India) · INMedical College of Wisconsin · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Salivary DuctsAnilidesAntineoplastic AgentsClass I Phosphatidylinositol 3-KinasesHumansMaleMiddle AgedMutationNeoplasm StagingNitrilesReceptors, AndrogenSalivary Gland NeoplasmsThiazolesTosyl CompoundsAlpelisibAnilidesAntineoplastic AgentsbicalutamideClass I Phosphatidylinositol 3-KinasesNitrilesPIK3CA protein, humanReceptors, AndrogenThiazolesTosyl Compounds

Identifiers

PMID34036229
PMCPMC8140801
OpenAlexW3159314118

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.